[NEW RESOURCE] Considerations for Optimizing the COVID19 Vaccine Country Portfolio

Published on August 29, 2022

Please find the link to an updated guidance and recommendations on COVID-19 vaccines and strategies (ENGLISH):

Considerations for optimizing the COVID-19 vaccine country portfolio (technet-21.org)

 

You can also find attached the FRENCH version of this this slide deck in TechNet21:

Facteurs à prendre en considération pour l'optimisation du portefeuille national de vaccins contre la COVID-19 (technet-21.org)

 

Updated in this version from January 2022 version:

  • Vaccination strategy:

    • 3 reasons why COVID-19 vaccination remains a key priority in the current pandemic context

    • Update on Global COVID-19 vaccination strategy and rolling allocation

  • Policy guidance

    • Definition of additional booster dose and hybrid immunity

    • Update on vaccine effectiveness against Omicron

    • WHO interim statement on the use of additional booster doses of EUL mRNA vaccines (17 May 2022)

    • WHO interim statement on composition of current COVID-19 vaccines and decision-making considerations for the use of variant updated COVID-19 vaccines (June 2022)

  • COVID-19 vaccine product recommendation

    • Interim recommendations for use of the CanSinoBIO Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19 (19 May 2022)

    • Updated WHO interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine (6 June 2022